TRANSCEND-T2D-1 is a 40-week, placebo-controlled phase 3 retatrutide study in 537 adults whose type 2 diabetes was inadequately controlled with diet and exercise alone. Its primary outcome was the change in HbA1c, a laboratory measure of average blood glucose over time. Weight was a separate outcome in the trial.
What did the A1C results show?
The paper reported greater mean reductions in HbA1c across the assigned retatrutide groups than with placebo at week 40. The differences are changes in percentage points of HbA1c. A one-point decrease from 8% to 7% is a simple example of the unit. It is not the same as a 1% relative decrease.
Who was studied?
The study enrolled adults at sites in the United States, Mexico and India. Participants had defined HbA1c and body-mass-index eligibility requirements. Because the trial examined a population without recent diabetes medication under the study’s entry rules, its results should be read in that context.
How does this differ from TRIUMPH-2?
TRIUMPH-2 focused on weight change in adults with type 2 diabetes and overweight or obesity. Many participants were already taking oral glucose-lowering medicines. The trials differ in population, treatment background, primary outcome and length. Reading them together is useful when you keep those differences visible.
Where should readers look for safety details?
The primary paper describes adverse events and discontinuations. Use its tables rather than inferring safety from a change in A1C. The findings summarize a monitored trial population. As of November 6, 2026, retatrutide remained investigational in the United States.
Sources and further reading
TRANSCEND-T2D-1 peer-reviewed report · TRANSCEND-T2D-1 trial registration · TRIUMPH-2 report · FDA’s information on unapproved GLP-1 drugs
GLP Life Sciences research library · Existing TRIUMPH-1 research summary